临床阶段眼科生物科技公司拨康视云-B（02592）今日在港交所挂牌上市，盘中大跌7.43%，引发市场关注。
拨康视云-B此前以每股10.1港元的价格完成全球发售，共发行6058.2万股股份，募集资金净额约5.22亿港元。公司香港公开发售部分获得78.78倍超额认购，显示出投资者的热烈兴趣。然而，这种热情似乎并未延续到二级市场。
尽管IPO认购火热，但拨康视云-B上市首日表现不佳可能与多重因素有关。作为一家临床阶段的生物科技公司，投资者可能对其短期盈利能力持谨慎态度。此外，近期市场对新股的态度趋于保守，加上整体市场情绪低迷，也可能影响了该股的表现。投资者需密切关注公司后续的临床试验进展和商业化进程，以评估其长期发展潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.